Last update: July 23, 2016


Low Risk for breastfeeding

Moderately safe. Probably compatible.
Mild risk possible. Follow up recommended.
Read the Comment.

Antiprogestin which derives from Norethisterone that is used for abortion, both as an abortifacient and induction of labor.

Its high plasma protein-binding capacity explains that excretion into breast milk is clinically non-significant. It achieves very low levels in breast milk at a maternal dose of 600 mg or undetectable at maternal dose of 200 mg.

Mifepristone does not interfere with the secretion of Prolactin. Some authors found that it may facilitate the early initiation of breastfeeding.

As in addition it is usually used for short periods, stopping breastfeeding is not required.

When used with semi-experimental purposes due to its anti-androgenic and antiglucocorticoid properties a continuous administration and / or large doses is required. There is no experience in connection with breastfeeding.
Those pathologies in which it is often used on a continuous basis by themselves are not compatible with breastfeeding.


We do not have alternatives for Mifepristone.

Suggestions made at e-lactancia are done by APILAM´s pediatricians and pharmacists, and are based on updated scientific publications.
It is not intended to replace the relationship you have with your doctor but to compound it.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.

Other names

Mifepristone is also known as

Mifepristone in other languages or writings:


Variable Value Unit
Oral Bioavail. 69 %
Molecular weight 430 daltons
Protein Binding 98 %
VD 1,5 l/Kg
Tmax 1,5 hours
T1/2 18 hours
M/P ratio 0,01 - 0,04 -
Relative Dose 0,5 - 1,5 %


  1. AEMPS. Mifepristona. Ficha técnica. 2015 Full text (in our servers)
  2. Sääv I, Fiala C, Hämäläinen JM, Heikinheimo O, Gemzell-Danielsson K. Medical abortion in lactating women--low levels of mifepristone in breast milk. Acta Obstet Gynecol Scand. 2010 Abstract
  3. Castinetti F, Fassnacht M, Johanssen S, Terzolo M, Bouchard P, Chanson P, Do Cao C, Morange I, Picó A, Ouzounian S, Young J, Hahner S, Brue T, Allolio B, Conte-Devolx B. Merits and pitfalls of mifepristone in Cushing's syndrome. Eur J Endocrinol. 2009 Abstract
  4. Hapangama D, Neilson JP. Mifepristone for induction of labour. Cochrane Database Syst Rev. 2009 Abstract
  5. Grunberg SM, Weiss MH, Russell CA, Spitz IM, Ahmadi J, Sadun A, Sitruk-Ware R. Long-term administration of mifepristone (RU486): clinical tolerance during extended treatment of meningioma. Cancer Invest. 2006 Abstract
  6. Weingertner AS, Hamid D, Baldauf JJ, Nisand I. [Present and potential uses of mifepristone in gynecology, obstetrics and other medical specialties]. J Gynecol Obstet Biol Reprod (Paris). 2004 Abstract
  7. FDA. Mifepristone. Drug Summary. 2004 Full text (in our servers)
  8. Baird DT. Antigestogens. Br Med Bull. 1993 Abstract

Total visits


Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write to us at

e-lactancia is a resource recommended by Academy of Breastfeeding Medicine from United States of America

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM